Houston biotech co. raises $11M to advance ALS drug development

drug money

Coya Therapeutics plans to scale up manufacturing and prepare for the commercialization of COYA 302, its ALS therapy drug. Photo via Getty Images

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

From Your Site Articles
Houston-based Mati Carbon won the global XPRIZE Carbon Removal competition, funded by The Musk Foundation earlier this year. Photo via LinkedIn.

Meet 6 of the fastest-growing scaleup companies in Houston right now

meet the finalists

From raising funding rounds to earning FDA acceptance, some of Houston's most innovative companies have reached major milestones this year.

The 2025 Houston Innovation Awards will recognize their progress by bringing back our Scaleup of the Year category for the second year. The award honors an innovative later-stage startup that's recently reached a significant milestone in company growth.

Six breakthrough businesses have been named finalists for the 2025 award. They range from climatetech startups to a biotech company developing new drugs for neurodegenerative diseases and more.

Read more about these businesses and their impressive growth below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation. Corporate 10-packs, featuring reserved seating and custom branding, and individual tickets are still available. Secure your seats today.

Coya Therapeutics

Clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has developed COYA-302 that enhances anti-inflammatory T cell function and suppresses harmful immune activity. The drug candidate is being advanced for several neurodegenerative diseases—including ALS, Alzheimer’s, Parkinson’s, and frontotemporal dementia—and has demonstrated promising reductions in neuroinflammation in preclinical and early clinical studies, according to the company.

Coya, founded in 2021, received FDA acceptance for its investigational new drug application for COYA-30 this summer. It closed its IPO in January 2023 for more than $15 million and added $26 million in PIPE funding that same year. Last year, the company secured an additional $15 million in PIPE funding.

Fervo Energy

Houston-based Fervo Energy is working to provide 24/7 carbon-free energy through the development of cost-competitive geothermal power. The company is developing its flagship Cape Station geothermal power project in Utah, which is expected to generate 400 megawatts of clean energy for the grid. The first phase of the project will supply 100 megawatts of power beginning in 2026. The second phase is scheduled to come online by 2028.

The company raised $205.6 million in capital to help finance the project earlier this year and fully contracted the project's capacity with the addition of a major power purchase agreement from Shell. Founded in 2017 by CEO Tim Latimer and CTO Jack Norbeck, Fervo is now a unicorn, meaning its valuation as a private company has surpassed $1 billion. In March, Axios reported Fervo is targeting a $2 billion to $4 billion valuation in an IPO.

Koda Health

Houston-based Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

Mati Carbon

Houston climatetech company Mati Carbon removes carbon through its Enhanced Rock Weathering (ERW) program that works with agricultural farms in Africa and India. Mati says the farmers it partners with are some of the most vulnerable to the impacts of climate change. The nonprofit won the $50 million grand prize in the XPRIZE Carbon Removal competition, backed by Elon Musk’s charitable organization, The Musk Foundation, earlier this year.

Mati Carbon scaled operations in India, Zambia, and Tanzania this year and has advanced its proprietary measurement, reporting and verification (MRV) platform, known as matiC, enabling seamless field data capture, chain-of-custody and carbon accounting at scale. The company was founded in 2022 by co-directors Shantanu Agarwal and Rwitwika Bhattacharya.

Molecule

Houston-based Molecule Software has developed an energy trading risk management (ETRM) platform that allows companies trading power, oil and gas, biofuels, renewables and more stay ahead as the markets evolve.

The company closed a Series B round earlier this year for an undisclosed amount. Sameer Soleja, founder and CEO of Molecule, said at the time that the funding would allow the company to "double down on product innovation, grow our team, and reach even more markets." The company was founded in 2012 by CEO Sameer Soleja and participated in the Surge Accelerator the same year.

Utility Global

Houston-based Utility Global has developed its proprietary eXERO technology that produces low-cost, clean hydrogen from water and industrial off-gases without requiring grid electricity.

First founded in 2018 by CEO Parker Meeks, the company participated in Greentown Labs and the Rice Alliance for Technology and Entrepreneurship programs. It raised a $55 million funding round earlier this year and launched commercial partnerships with ArcelorMittal Brazil and Hanwha Group in South Korea to deploy its hydrogen solutions at scale.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

This week's roundup of Houston innovators includes Reginald DesRoches of Rice University, Tatiana Fofanova of Koda Health, and Arun Swaminathan of Coya Therapeutics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across academia and health care innovation.

Reginald DesRoches, president of Rice University

Rice University President Reginald DesRoches joins the Houston Innovators Podcast to discuss balancing tradition with growth, innovation, and global impact in education. Photo courtesy Tommy LaVergne/Rice University

How does a historic university maintain its legacy while still making room for growth and increased opportunities? That's what Rice University President Reginald DesRoches considers with every decision he makes.

"It's this idea of preserving what's special about the university, while also knowing we need to adapt to a new time, a new Rice, a new time in higher ed, and a new time in society," DesRoches says on the Houston Innovators Podcast.

"There's a healthy tension between preserving what Rice is known for — the culture of care, the close-knit community — while knowing that we need to grow, have a global impact, and position Rice on a global scale. It's something that's constantly in my mind to make sure we do both." Continue reading.

Tatiana Fofanova, CEO of Koda Health

Koda Health has a new service for the 37 million Americans living with Chronic Kidney Disease. Photo courtesy of Koda Health

Chronic Kidney Disease is expensive and common. In fact, 37 million Americans live with the condition. The winner of this year’s Houston Innovation Award for best female-founded business, Koda Health, recognized the need for help among CKD sufferers and has answered the call.

Last week, Koda Health announced the addition of Kidney Action Planning to its suite of services for patients with serious illnesses.

"Kidney Action Planning is designed to fill a significant void in CKD management," Tatiana Fofanova, CEO of Koda Health, says in a statement. "Some studies indicate greater than 70 percent of patients start dialysis in the ER suboptimally, potentially navigating a life-or-death scenario. This is both frightening and largely avoidable with an intervention like Kidney Action Planning, which helps patients better understand CKD.” Continue reading.

Arun Swaminathan, CEO of Coya Therapeutics

Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients. Continue reading.

Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

These five scaleups stood out to the judges of the 2024 Houston Innovation Awards. Photo via Getty Images

Meet 5 of the fastest-growing scaleup companies in Houston

houston innovation awards

The 2024 Houston Innovation Awards will feature a new category: Scaleup of the Year, which honors a Bayou City company that's seen impressive growth in 2024.

From biotech companies to decarbonization startups, the inaugural finalists have expanded internationally, moved to larger facilities, completed clinical trials and more. Read on to learn more about these fast-growing startups.

Secure your tickets to the 2024 Houston Innovation Awards next Thursday, November 14, at TMC Helix Park.


Cart.com, a unified commerce and logistics solutions provider for B2C and B2B companies

With the acquisition of Amify, Cart.com has expanded its workforce and grown its suite of services. Photo courtesy of Cart.com

Clinching unicorn status with its 2023 series C raise, Cart.com is on a mission to unify commerce across sales and distribution channels and digital and physical capabilities with its omnichannel enterprise-grade software, services and logistics.

Founded in 2020 with nine acquisitions and $759.2 million raised to date, according to Crunchbase, Cart.com's recent achievements includes acquiring Pacsun’s fulfillment operators, brining a 2 million-square-foot facility online, expanding its executive team, and more.

"In the last 12 months, Cart.com has dramatically grown its fulfillment network’s scale and technological capabilities," writes CEO Omail Tariq in his Houston Innovation Awards application.

"We have been laser-focused on improving quality, performance and efficiency at scale while continuing to aggressively grow our customer base, expand our capabilities to customers in new industries and grow our physical presence to new locations," he continues. "Prioritizing our strategic growth initiatives has been critical in the current macroeconomic environment as profitable growth remains paramount for our team."

In 2021, Cart.com moved its headquarters to Austin, with most of the leadership team remaining in Houston. Two years later, the company announced its HQ return to the Bayou City.

"We've found Houston's business and university communities to be incredibly supportive of our efforts and have found the city to be a place that is both easier and more affordable to bring together our global employee population at more regular intervals," Tariq adds in the app.

Coya Therapeutics, a clinical-stage company developing therapies for neurodegenerative, autoimmune, and metabolic diseases

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPOCoya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Revolutionary biotech company Coya Therapeutics Inc. (NASDAQ: COYA) may have closed its IPO in January 2023 for more than $15 million, but the company has made some of its most significant strides in the development of its lead product that prevents the further spreading of neurodegenerative diseases this year.

Known as COYA 302, the product uses a unique dual mechanism that is now being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease. The company published its phase 1 proof-of-concept study in the peer-reviewed journal Frontiers in Neurology that showed COYA 302's ability to stop clinical progression in ALS at 24 weeks in combination therapy, which helped earn the company a $5 million in strategic investment from the Alzheimer’s Drug Discovery Foundation to continue to develop the product for a planned Phase 2 trial focused on FTD.

Last year the company also added to its C Suite, naming Dr. Arun Swaminathan as chief business officer and Dr. Fred Grossman as president and chief medical officer.

Coya merged with Nicoya Health Inc. and raised $10 million in its series A in 2020.

NanoTech Materials, a chemical manufacturer that integrates novel heat-control technology with thermal insulation, fireproofing, and cool roof coatings to drastically improve efficiency and safety

Growing Houston startup moves into 43,000-square-foot facility amid 'hypergrowth phase'NanoTech Materials celebrated its move into a new facility — a 43,000-square-foot space in Katy, Texas, this week

Mike Francis, co-founder and CEO of NanoTech Materials, told InnovationMap earlier this year that it was in a "hype growth" phase—and meant it.

NanoTech, known for its proprietary Insulative Ceramic ParticleTM (ICP) that uses nanotechnology to optimize energy efficiency and heat control in the built environment, expanded into a new 43,000-square-foot facility this year and tripled its valuation in the last two years, according to its Innovation Awards application. The company also expanded into the Middle East and Singapore and successfully scaled up its NanoTech Cool Roof Coat to commercial markets.

The company closed a $5 million seed round in 2020 and an oversubscribed Series A round last year for $13 million. It was the first company selected for the Houston-based Halliburton Labs in 2021 and joined the Rice Alliance Clean Energy Accelerator in 2023.

Square Robot, an advanced robotics company serving the energy industry and beyond by providing submersible robots for storage tank inspections

Square Robot has a team of 15 in Houston. Photo courtesy\u00a0of Square Robot

Submersible robotics company Square Robot launched its Houston office in 2019 and expanded in the Bayou City this past year.

According to the company's Innovation Award application, the company doubled its fleet of autonomous, submersible robots that service the energy industry, deploying to Malaysia, Vietnam, Thailand, Australia, Kuwait and Saudi Arabia. Its robots are specifically used for storage tank inspections and eliminating the need for humans to enter dangerous and toxic environments.

Square Robot moved to a new, customer-facing Houston facility this year and also developed a new innovative technology that's able to gather phased ultrasonic readings on insulated tank shells while the tank is operational.

The company closed a Series A round in 2018 for $6 million.

Syzygy Plasmonics, a company that's decarbonizing chemical production with a light-powered reactor platform that electrifies the production of hydrogen, syngas, and fuel with reliable, low-cost solutions

Houston climatetech startup selected for inaugural global entrepreneur competitionSyzygy Plasmonics is going to be competing in Gastech's new startup competition. Photo courtesy of Syzygy

Known for the world’s first light-powered reactor cell for industrial chemical reactions, Syzygy Plasmonics began taking orders earlier this year for its Rigel reactor cell after meeting initial performance targets. The cell enables a customer to produce up to five tons of low-carbon hydrogen per day.

The groundbreaking technology earned the company regional, national and global attention. Fast Company magazine placed the company on its energy innovation list. It was also named a finalist for Ernst & Young’s Entrepreneur Of The Year 2024 Gulf South Award and was invited to participate in Gastech's global entrepreneur competition.

The company most recently raised $76 million in a Series C round in 2022.

This week's roundup of Houston innovators includes Howard Berman of Coya Therapeutics, Elad Inbar of RobotLAB, and Steve Altumus of Intuitive Machines. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a robotics expert, a space tech leader, and a therapeutics CEO.

Howard Berman, co-founder and CEO of Coya Therapeutics

This week's episode of the Houston Innovators Podcast revisits a conversation with Howard Berman, co-founder and CEO of Coya Therapeutics. Photo courtesy of Coya

It's been a busy summer for Houston-based Coya Therapeutics, a clinical-stage biotech company that's creating revolutionary treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS.

In July, Coya announced that has expanded its collaboration with Houston Methodist Research Institute, or HMRI. The publicly traded company also announced fresh funding from the Johnson Center for Cellular Therapeutics.

Last month, Coya reported that it has expanded its treatment research to see how GLP-1 drugs — a trending drug for weight loss — can enhance the effects of its proprietary therapeutics. By combining the medicines, Howard Berman, co-founder and CEO of Coya Therapeutics, says he thinks Coya can better treat these complex immune-based diseases. Read more.

Elad Inbar, founder and CEO of RobotLAB

Elad Inbar is the founder and CEO of RobotLAB. Photo courtesy of RobotLAB

Elad Inbar, founder and CEO of RobotLAB, who in July expanded his company’s Texas franchise operations with the opening of a Houston branch.

“For many years, robots were toys — for geeks. You had to build them yourself, program them yourself,” Inbar says.

But the electronics revolution that brought handheld phones to the mainstream inspired Inbar to turn that concept to robotics when he formed RobotLAB in 2007.

“To me, this was completely a wake up call — seeing the market shift, and you know, bringing the opportunity to the mass market,” he says. Read more.

Steve Altemus, co-founder, president, and CEO of Intuitive Machines

Per the contract, Intuitive Machines will provide near space communications and navigation services for NASA. Photo via intuitivemachines.com

Houston-based space exploration, infrastructure, and services company Intuitive Machines has snagged a deal with NASA that could be worth more than $4 billion.

Under the contract, Intuitive Machines (Nasdaq: LUNR, LUNRW) will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. In total, the contract could be worth $4.82 billion. The initial round of NASA funding runs from October 2024 through September 2029.

“This contract marks an inflection point in Intuitive Machines’ leadership in space communications and navigation,” Steve Altemus, CEO of Intuitive Machines, says. Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Uber, Nuro and Lucid plan to roll out robotaxi services in Houston

autonomous autos

More autonomous vehicles are expected to hit the roads in Houston next year.

Ridesharing giant Uber announced that it plans to roll out its premium robotaxi service in the Bayou City in mid-2027. Houston will be Uber’s second planned market for the program, following the San Francisco Bay Area, where the program is expected to be rolled out later this year.

Uber, Nuro and Lucid Group will bring the robotaxi program to Houston with more markets planned for the future. Currently, Nuro is conducting autonomous on-road testing with safety operators in Houston. Testing includes simulation, closed-course testing and supervised public-road testing.

“Houston is a city Nuro knows well, and we’re excited to help bring this robotaxi service to the city through our partnership with Uber and Lucid,” Andrew Chapin, chief operating officer at Nuro, said in a news release. “Houston’s large, complex metro area is an ideal market for demonstrating how Nuro’s universal autonomy platform can generalize across different geographies and operating environments. We look forward to continued engagement with the community as we prepare to launch service in 2027.”

The fleet of 100 vehicles across California and Texas will feature Lucid Gravity EVs and future Lucid Midsize vehicles equipped with Nuro Driver technology, Nuro’s Level 4 universal autonomy platform, plus a redundant sensor suite with cameras, lidar, radar and a roof-mounted halo.

The vehicles will be owned and operated by Uber and its fleet partners and made available to riders through the Uber network, according to the company.

In addition to the fleet of autonomous vehicles, Uber also announced that it has secured a 50,000-square-foot depot facility and dedicated charging pitstop in Houston. The facility will allow Uber and its partners to control vehicle maintenance, repairs, charging, cleaning, and day-to-day operations.

“Houston marks an important next step in our partnership with Lucid and Nuro as we expand autonomous mobility to more riders throughout the world,” Sarfraz Maredia, global head of autonomous mobility & delivery at Uber, added in the release. “Together, we’re combining best-in-class vehicle and autonomy technology with Uber’s scale, fleet operations expertise, and infrastructure capabilities to build a service that can grow across dozens of markets in the years ahead.”

Waymo launched its autonomous vehicle program in Houston in February.

The company later suspended its driverless car services in Houston, other major Texas cities, and Atlanta, after one of its vehicles was stranded by flooding during heavy rains. However, according to the Houston Chronicle, the fleet has resumed activity in Houston and is fully active.

Houston fintech company closes $7M funding round

fintech funding

Houston-based fintech company Receipts Depositary Corporation has closed a $7 million oversubscribed funding round and plans to scale.

The round was led by Austin-based LiveOak Ventures, with participation from Hivemind Capital, Onigiri Capital, OTC Markets Group, GTS, and Redbeard Ventures, according to a release from RDC.

RDC's platform issues depositary receipts (DRs) to qualified investors on digital and alternative assets, making it easier for investors to buy and trade hard-to-access and less traditional assets. Currently, the company offers DRs for cryptocurrencies including Bitcoin, Ethereum, Solana and XRP.

RDC says the new funding will allow it to launch new DR products across a wider range of asset categories, potentially including commodities. Additionally, it plans to grow its relationships with "banks, broker-dealers, market makers, custodians and exchange partners" and add to its product, operations, technology, and commercial functions teams. The company is actively hiring, according to a press release.

“Depositary Receipts are trusted, regulated capital markets products which RDC is bringing to an entirely new universe of assets, from commodities to digital assets, that have historically been out of reach of traditional securities markets," Krishna Srinivasan, founding partner at LiveOak Ventures, said the release. “The team's depth of experience in the DR business on a global scale, combined with the broad institutional validation from co-investors, anchor customers, and strategic partners across asset classes, makes RDC uniquely positioned to define this category. We're proud to lead this round and support the company as it scales.”

RDC was founded in 2022 by three Citibank alumni: CEO Ankit Mehta, CEO Bryant Kim and COO Ishaan Narain. It began offering its first DRs for Bitcoin in 2024.

“This funding round is a strong validation of what we’re building at RDC and the growing demand for modernized Depositary Receipt infrastructure,” Mehta added in the release. “With the support of LiveOak Ventures and our investor partners, we are accelerating development across our DR platform expanding our market reach, and building the team needed to support the next generation of DR product

Houston space co. adds local colleges to university alliance

space schools

Houston’s Axiom Space has added 26 new members to its University Alliance—including two from Houston—to support the next generation of space exploration.

Engineers, researchers and students from the partnering universities will be dedicated to advancing microgravity research, technology development and commercial innovation in low-Earth orbit.

Rice University and the University of Houston are among the new colleges to join the alliance, which launched with 15 members last year. The University of Texas at Austin and the University of Texas at El Paso have also joined, in addition to international institutions in Europe, Asia and Australia, and others from around the U.S. See full list here.

“Through the University Alliance, Axiom Space is uniting the international research community driven to enable human progress,” Lucie Low, Axiom Space chief science officer, said in a news release. “Together, alliance members are taking the initiative to ensure microgravity research benefits everyone on Earth and our shared goals fulfill a scientific purpose to advance civilization.”

Axiom is building the world’s first commercial space station, known as Axiom Station. The University Alliance “will support and advance space science during the transition from government-led to commercially owned and operated space stations,” the company said in a release. Partnering universities will contribute to the research community by participating in international collaborative scientific initiatives, identifying future research, and bolstering strategic positions in the commercial orbit research field.

Recently, the Rice Space Institute was also selected to lead the U.S. Space Force Strategic Institute 4 in addition to other space-centric partnerships.

“We’re excited to bring our expertise to this global alliance and to benefit from the deep expertise of our partners,” David Alexander, professor of physics and astronomy and director of the Rice Space Institute, said in a news release. “Space is truly a collaborative and global endeavor. Alliances like these are key to progress.”

UH and NASA’s Johnson Space Center expanded their collaboration in 2022. In 2024, UH launched its NASA MIRO Inflatable Deployable Environments and Adaptive Space Systems Center (IDEAS2) via a five-year, $5 million grant.

“As a major public research university located in Space City, the University of Houston has a unique opportunity and responsibility to help lead the future of space innovation, and our participation in Axiom Space’s University Alliance represents a major step forward in that mission,” Karolos Grigoriadis, the Hugh Roy and Lillie Cranz Cullen Endowed Professor and chair of mechanical and aerospace engineering at UH, added in a separate release.

Meanwhile, Axiom recently tacked on an additional $175 million to a previously announced capital raise, bringing the oversubscribed round to a total of more than $525 million. It also has announced plans to launch Swiss and Japanese subsidiaries.

View All Listings